Analysts expect BioMarin Pharmaceutical to report Q2 2026 revenue of $931.3 million and non-GAAP EPS of $0.79, while the stock currently trades at $60.02, well below its $87.70 average analyst price target.
The primary focus for investors is the integration of Amicus Therapeutics following its $4.8 billion acquisition, which is projected to drive top-line growth via the Galafold and Pompe disease franchises.
Management recently raised full-year 2026 revenue guidance to over $3.8 billion, anticipating that the expanded portfolio will offset near-term earnings pressure from integration costs. Voxzogo demand remains a critical growth driver as the company prioritizes specialized therapies following the voluntary market withdrawal of the Roctavian gene therapy program.